What Does Wall Street Think About Insmed Incorporated (INSM)?

Insmed Incorporated (NASDAQ:INSM) is one of the best hot large cap stocks to buy according to hedge funds. In a report released on August 22, Liisa Bayko from Evercore ISI maintained a Buy rating on Insmed Incorporated (NASDAQ:INSM) with a price target of $110.00.

The company also received a Buy from Mizuho Securities’s Graig Suvannavejh in a report issued on August 21.

The same day, Morgan Stanley analyst Maxwell Skor raised the firm’s price target on Insmed Incorporated (NASDAQ:INSM) to $144 from $126, keeping an Equal Weight rating on the shares.

The analyst told investors that conversations held with management and a key opinion leader physician led the firm to revise its model to take into account the broader lifecycle potential of the company’s portfolio and the durability of brensocatib’s cash flows.

Insmed Incorporated (NASDAQ:INSM) is a global biopharmaceutical company that develops and commercializes therapies for patients with rare diseases. The company focuses on the Brensocatib and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline.

While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.